CA2410153C

CA2410153C - A novel bacillus thuringiensis strain, crystal gene and crystal protein and uses thereof

Info

Publication number: CA2410153C
Application number: CA2410153A
Authority: CA
Inventors: Jean-Charles Cote; Yong-Chul Jung; Eiichi Mizuki; Tetsuyuki Akao
Original assignee: Agriculture and Agri Food Canada AAFC
Current assignee: Agriculture and Agri Food Canada AAFC
Priority date: 2002-12-05
Filing date: 2002-12-05
Publication date: 2013-04-23
Anticipated expiration: 2022-12-05
Also published as: CA2410153A1

Abstract

A novel Bacillus thuringiensis strain deposited at the International Depository Authority of Health Canada in Winnipeg under accession number IDAC010201-5, its crystal gene having the sequence SEQ ID NO: 1 and crystal protein encoded by same having the sequence SEQ ID NO: 2 and uses thereof. More specifically, the present invention is concerned with a novel Bacillus thuringiensis, novel cry31 protoxin and toxin, nucleotide sequences encoding same and anti-cancer therapeutic applications for the toxin.

Description

TITLE OF THE INVENTION
A NOVEL BACILLUS THURINGIENSIS STRAIN, CRYSTAL GENE AND
CRYSTAL PROTEIN AND USES THEREOF

FIELD OF THE INVENTION

[0001] The present invention relates to a novel Bacillus thuringiensis strain, crystal gene and crystal protein and uses thereof. More specifically, the present invention is concerned with a novel Bacillus thuringiensis, novel Cry3l protoxin and toxin, nucleotide sequences encoding same and anti-cancer therapeutic applications for the toxin.

BACKGROUND OF THE INVENTION

[0002] Bacillus thuringiensis has been known for years for coding for 6-endotoxin crystal proteins. A large variety of endotoxins have been described and characterized, many of them having reported insecticidal activities. Most of these have molecular weights in the range of 130-140KDa and 65-80KDa (Schnepf et al., 1998). Recently, a novel endotoxin protein has been identified and designated Cry3l Aal (also called parasporin) (Mizuki et al., 2000). It is an 81 KDa protein encoded by a 2169 bp gene that has been characterized as having a selective activity as a human Leukemic Cell-Recognizing Protein (Mizuki et al., (1999) and (2000)). No other member of this novel family of endotoxin has yet been reported.

[0003] It is therefore an object of the present invention to provide a new bacillus thuringiensis strain expressing a new member of this novel family of b-endoxins displaying advantageous cytotoxicity against human cancer cells.

SUMMARY OF THE INVENTION

[0004] More specifically, in accordance with the present invention, there is provided a novel Bacillus thuringiensis strain, named M15, a novel 83-kDa crystal protein 6-endotoxin assigned the designation Cry31Aa2 by the Bacillus thuringiensis Pesticide Crystal Protein Nomenclature Committee and displaying cytotoxicity against certain human cancer cells.

[0005] According to a first aspect of the present invention, there is also provided a biologically pure culture of a microorganism strain comprising all of the identifying characteristics of a Bacillus thuringiensis strain deposited at the International Depository Authority of Health Canada in Winnipeg under accession number IDAC010201-5, or a mutant thereof isolated from said strain, said mutant comprising all of said biochemical characteristics and producing a crystal protein having cytotoxicity against human cancer cells..

[0006] According to a second aspect of the present invention, there is also provided an isolated nucleic acid molecule comprising:

(a) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:2;

(b) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:8;

(c) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:14;

(d) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:13, with the proviso that said nucleotide sequence does not encode the amino acid sequence at positions 232 to 723 of SEQ ID NO:18;

(e) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:15, with the proviso that said nucleotide sequence does not encode the amino acid sequence at positions 232 to 723 of SEQ ID NO:18;

(f) a nucleotide sequence comprising the nucleotide sequence set forth in SEQ ID NO:1 or 9;

(g) a nucleotide sequence encoding a crystal protein cytotoxic against at least one human cancer cell, the crystal protein having at least 94%
identity with the complete amino acid sequence in SEQ ID NO:2;

(h) a nucleotide sequence encoding a crystal protein cytotoxic against at least one human cancer cell, the crystal protein having at least 97%
identity with the complete amino acid sequence in SEQ ID NO:8;

(i) a nucleotide sequence completely complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g) and (h); or Q) a nucleotide sequence encoding a crystal protein cytotoxic against at least one cancer cell, which hybridizes under high stringency conditions to the nucleotide sequence in (i), wherein the high stringency conditions comprise hybridization in 5X SSC, 5X Denhardt's solution, 1% SDS
and 100 pg/ml of carrier DNA at 65 C followed by washing in 0.2X SSC, 0.1%
SDS at 65 C.

[0007] According to another aspect of the present invention, there is also provided an isolated polypeptide comprising:

(a) an amino acid sequence as set forth in SEQ ID NO:2;
(b) an amino acid sequence set forth in SEQ ID NO:8;

(c) an amino acid sequence as set forth in SEQ ID NO:14;

(d) an amino acid sequence as set forth in SEQ ID NO:13, with the proviso that said amino acid sequence is not the sequence at positions 232 to 723 of SEQ ID NO:18;

(e) an amino acid sequence as set forth in SEQ ID NO:15, with the proviso that said amino acid sequence is not the sequence at positions 232 to 723 of SEQ ID NO:18 (f) a crystal protein having at least 94% identity with the complete amino acid sequence of SEQ ID NO:2, wherein the protein becomes cytotoxic upon treatment with trypsin; or (g) a crystal protein cytotoxic against at least one cancer cell and having at least 97% identity with the complete amino acid sequence of SEQ ID NO:8.

[0008] According to another aspect of the present invention, there is also provided a recombinant vector comprising an isolated nucleic acid molecule of the present invention, a recombinant host cell same, a method for making same comprising inserting such isolated nucleic acid molecule in a vector.

[0009] According to another aspect of the present invention, there is also provided a recombinant method for producing a cytotoxic polypeptide, comprising culturing the host cell under conditions such that the polypeptide is expressed and recovering the polypeptide.

[0010] According to another aspect of the present invention, there is also provided an isolated antibody that binds specifically to a polypeptide of the present invention.

[0010a] In an embodiment, the antibody specifically binds to:

(a) an amino acid sequence as set forth in SEQ ID NO:2;
(b) an amino acid sequence as set forth in SEQ ID NO:8;
(c) a crystal protein having at least 94% identity with the complete amino acid sequence of SEQ ID NO:2, wherein said protein becomes cytotoxic upon treatment with trypsin; or (d) a crystal protein cytotoxic against at least one human cancer cell and having at least 97% identity with the complete amino acid sequence of SEQ ID NO:8.

[0011] According to another aspect of the present invention, there is also provided a method of modulating the level of cry31Aa2 active protein in a cell comprising a modulation of the level or activity of the sequence SEQ ID
NO:8.

[0012] According to another aspect of the present invention, there is also provided an in vitro method of using a polypeptide of the present invention for lysing a human cancer cell which according a specific embodiment of the present invention is a HELA, TCS, HL-60, Jurkat, or Hep-G2 cell.

[0013] According to another aspect of the present invention, there is also provided an in vitro method of testing the cytotoxicity of a polypeptide of the present invention against a candidate cancer cell comprising determining the EC50 of the polypeptide on the candidate cell, wherein the polypeptide is characterized as possessing cytotoxicity against the candidate cell if the of the polypeptide against the candidate cell is measurably lower than that against a normal T cell.

5a [0014] According to another aspect of the present invention, there is also provided an in vitro method for lysing a human cancer cell comprising applying a cytotoxic amount of a polypeptide of the present invention on a human cancer cell.

[0015] According to another aspect of the present invention, there is also provided a method for obtaining a cytotoxic polypeptide comprising cleaving a polypeptide of the present invention with a protease able to cleave between a residue R and a residue I. In an embodiment the residue R and the Residue I is an arginine at position 250 and an isoleucine at position 251 of SEQ ID NO:2. In a specific embodiment, the protease is trypsin.

[0016] In order to provide a clear and consistent understanding of terms used in the present description, a number of definitions are provided hereinbelow.

[0017] Unless defined otherwise, the scientific and technological terms and nomenclature used herein have the same meaning as commonly understood by a person of ordinary skill to which this invention pertains.
Generally, the procedures for molecular biology methods and the like are common methods used in the art. Such standard techniques can be found in reference manuals such as for example Sambrook et al. (1989, Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) and Ausubel et al. (1994, Current Protocols in Molecular Biology, Wiley, New York).

[0018] The terminology "human cancer cell" as used herein refers to cells associated with at least one type of cancer. Without limiting the generality of this definition, this terminology includes the following cells and corresponding tissues, namely acetabulum: HT-1080; amnion: WISH; B-cells: NAGL-1;
blood: J-111, IM-9, jurkat; bone: HOS, MG-63, MEG-01; bone marrow: A549;
MEG-01; FS-1; brain: SF126, U-251, MG, Becker, Marcus, T98G, SK-MG-1, ONS-76, KNS, B2-17, no. 10, no. 11, KALS-1, KINGS-1, KS-1, KNS-81-FD, NMC-G1, GB-1, AM-38, YH-13; colon: WiDr, LoVo, CCD 841, CCD-33, Caco-2; embryonic limb: Miz-1; epidermoid: A-431; whole fetus: HE-1; foreskin:
FLOW7000, Hs68, liver: Chang Liver, Alexander cells, HC, Hep-G2; lung:
MRC-5, MRC-9, HFL1, WI-38, Flow 2000, KNS-62; lymph node: GAK;
lymphoblastoid: Namalwa; maxilla: Raji; melanoma: G-361, A2058;
neuroblastoma: KP-N; ovary: RMG, RKN, RTSG, RMUG; peripheral blast:
MTA; peripheral blood: RPMI 8226, HL-60, CCRF-SB, EB-3, RPMI 788, NC-37, MOLT-4, KU812, CCRF-CEM, CMK, NOMO, NKM-1, MEG-A2, TMD5, KA13;
pleural effusion: U-937; prostate: DU145, CEACAM-1; sympatho-adrenal cell:
IMR-32, NB-1; umbilical cord: HUV-EC-C; uterine cervix: Ca Ski, HeLa, SKG, BOKU; uterine endometrium : SNG; uterus: SKN, NJG, SAWANO, TCS, UtSMC. The terminology "cancer cell" also refers herein to cells associated with non-human forms of cancer including Vero, COS-7 and NIH3T3 cells.

[0019] As used herein, a "biologically pure" strain is intended to mean the strain separated from materials with which it is normally associated in nature. Note that a strain associated with other strains, or with compounds or materials that it is not normally found with in nature, is still defined as "biologically pure." A monoculture of a particular strain is, of course, "biologically pure."

Nucleotides [0020] Nucleotide sequences of the present invention are presented herein by single strand, in the 5' to 3' direction, from left to right, using the one letter nucleotide symbols as commonly used in the art and in accordance with the recommendations of the IUPAC-IUB Biochemical Nomenclature Commission.

[0021] The present description refers to a number of routinely used recombinant DNA (rDNA) technology terms. Nevertheless, definitions of selected examples of such rDNA terms are provided for clarity and consistency.

[0022] As used herein, "nucleic acid molecule", refers to a polymer of nucleotides. Non-limiting examples thereof include DNA (e.g. genomic DNA, cDNA), RNA molecules (e.g. mRNA) and chimeras thereof. The nucleic acid molecule can be obtained by cloning techniques or synthesized. DNA can be double-stranded or single-stranded (coding strand or non-coding strand [antisense]).

Protein expression [0023] Prokaryotic expressions are useful for the preparation of large quantities of the Cry31Aa2 protoxine and toxine encoded by the cry3lAa2 DNA sequence. These proteins can be purified according to standard protocols that take advantage of the intrinsic properties thereof, such as size and charge (e.g. SDS gel electrophoresis, gel filtration, centrifugation, ion exchange chromatography...). In addition, the protein of interest can be purified via affinity chromatography using polyclonal or monoclonal antibodies.
The purified protein can be used for therapeutic applications in accordance with the methods and uses of the present invention.

Mutations, mutants and variants [0024] As commonly known, a "mutation" is a detectable change in the genetic material which can be transmitted to a daughter cell. As well known, a mutation can be, for example, a detectable change in one or more deoxyribonucleotides. For example, nucleotides can be added, deleted, substituted for, inverted, or transposed to a new position. Spontaneous mutations and experimentally induced mutations exist. A mutant polypeptide can be encoded from this mutant nucleic acid molecule.

[0025] As used herein, a "mutant" of the novel strain of Bacillus thuringiensis of the present invention namely the M15 strain deposited under access no, IDAC010201-5 may or may not have the same identifying biological characteristics of the M15 strain, as long as the mutant produces a crystal protein that is cytotoxic against human cancer cells.
Illustrative examples of suitable methods for preparing mutants and variants of the inventive microorganism strain include, but are not limited to:
mutagenesis by irradiation with ultraviolet light or X-rays, or by treatment with a chemical mutagen such as nitrosoguanidine (N-methyl-N'-nitro-N-nitrosoguanidine), methylmethanesulfonate, nitrogen mustard and the like; gene integration techniques, such as those mediated by insertional elements or transposons or by homologous recombination of transforming linear or circular DNA molecules;
and transduction mediated by bacteriophages such as P1. These methods are well known in the art and are described, for example, in J. H. Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1972); J. H. Miller, A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1992); M.
Singer and P. Berg, Genes & Genomes, University Science Books, Mill Valley, CA (1991); J. Sambrook, E. F. Fritsch and T. Maniatis, Molecular Cloning: A
Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); P. B. Kaufman et al., Handbook of Molecular and Cellular Methods in Biology and Medicine, CRC Press, Boca Raton, FL (1995);
Methods in Plant Molecular Biology and Biotechnology, B. R. Glick and J. E.
Thompson, eds., CRC Press, Boca Raton, FL (1993); and P. F. Smith-Keary, Molecular Genetics of Escherichia coli, The Guilford Press, New York, N.Y.
(1989).

[0026] Mutated strains derived from the M15 strain using known methods are then preferably selected or screened for improved cytotoxic crystal proteins production potential or for other desirable properties related to their utility in expressing crystal proteins that are cytotoxic to human cancer cells. In a specific embodiment of the mutagenesis and screening approach to strain improvement, mutagenized cells are selected on the basis of their cytopathic effects or cytocidal activity on target cells and their spectrum of action.

[0027] The term "variant" refers herein to a protein or nucleic acid molecule which is substantially similar in structure and biological activity to the protein or nucleic acid of the present invention and includes a cry3lAa2 nucleic sequence or the protein encoded by same having one or more mutations that does not affect its cytotoxic activity. In particular, a variant of the nucleotide or polypeptide sequence of the active portion of Cry31Aa2 possesses the ability to lyse human cancer cells including HeLa, TCS, HL-60, Jurkat and Hep-G2. The methods for determining whether a nucleotide or polypeptide sequence constitutes a variant of Cry31Aa2 include conducting an EC50 assay on a cancer cell against which the Cry31Aa2 active toxin displays cytotoxicity.

[0028] The functional derivatives of the present invention can be synthesized chemically or produced through recombinant DNA technology. All these methods are well known in the art.

Hybridization [0029] "Nucleic acid hybridization" refers generally to the hybridization of two single-stranded nucleic acid molecules having complementary base sequences, which under appropriate conditions will form a thermodynamically favored double-stranded structure. Examples of hybridization conditions can be found in the two laboratory manuals referred above (Sambrook et al., 1989, supra, and Ausubel et al., 1989, supra) and are commonly known in the art. In the case of an hybridization to a nitrocellulose filter, as for example in the well known Southern blotting procedure, a nitrocellulose filter can be incubated overnight at 65 C with a labeled probe in a solution containing 50% formamide, high salt (5 x SSC or 5 x SSPE), 5 x Denhardt's solution, 1% SDS, and 100 pg/mI denatured carrier DNA (e.g.
salmon sperm DNA). The non-specifically binding probe can then be washed off the filter by several washes in 0.2 x SSC/0.1 % SDS at a temperature which is selected in view of the desired stringency: room temperature (low stringency), 42 C (moderate stringency) or 65 C (high stringency). The selected temperature is based on the melting temperature (Tm) of the DNA
hybrid. Of course, RNA-DNA hybrids can also be formed and detected. In such cases, the conditions of hybridization and washing can be adapted according to well known methods by the person of ordinary skill. Stringent conditions will be preferably used (Sambrook et a!.,1989, supra). In most hybridizations, a 1%
mismatching of bases will lower the melting temperature by 1-1.5 C (Sambrook et a!.,1989, supra). Consequently, nucleotide sequences sharing 98%
nucleotide identities with the cry3lAa2 gene encoding the trypsin-activated portion of Cry31Aa2 will still hybridize with the cry3lAa2 gene when the melting temperature is lowered by 3 C, respective to the most stringent conditions for hybridization between two identical cry3lAa2 sequences. The term "high stringency" conditions refer herein to the conditions required for the hybridization of nucleotide sequences sharing at least 97% nucleotide identities with the cry3lAa2 gene encoding the trypsin-activated portion of Cry31Aa2.

[0030] As used herein, "chemical derivatives" is meant to cover additional chemical moieties not normally part of the subject matter of the invention. Such moieties could affect the physico-chemical characteristic of the derivative (e.g. solubility, absorption, half life, decrease of toxicity and the like).
Such moieties are exemplified in Remington's Pharmaceutical Sciences (1980).
Methods of coupling these chemical-physical moieties to a polypeptide or nucleic acid sequence are well known in the art.

Recombinant vectors [00311 The term "recombinant DNA" as known in the art refers to a DNA molecule resulting from the joining of DNA segments. This is often referred to as genetic engineering. The same is true for "recombinant nucleic acid".

[0032] The term "vector" is commonly known in the art and defines a plasmid DNA, phage DNA, viral DNA and the like, which can serve as a DNA
vehicle into which DNA of the present invention can be cloned. Numerous types of vectors exist and are well known in the art.

[0033] The term "expression" defines the process by which a gene is transcribed into mRNA (transcription), the mRNA is then being translated (translation) into one polypeptide (or protein) or more.

[0034] The terminology "expression vector" defines a vector or vehicle as described above but designed to enable the expression of an inserted sequence following transformation into a host. The cloned gene (inserted sequence) is usually placed under the control of control element sequences such as promoter sequences. The placing of a cloned gene under such control sequences is often referred to as being operably linked to control elements or sequences.

[0035] Operably linked sequences may also include two segments that are transcribed onto the same RNA transcript. Thus, two sequences, such as a promoter and a "reporter sequence" are operably linked if transcription commencing in the promoter will produce an RNA transcript of the reporter sequence. In order to be "operably linked" it is not necessary that two sequences be immediately adjacent to one another.

[0036] Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host or both (shuttle vectors) and can additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.

[0037] The DNA construct can be a vector comprising a promoter that is operably linked to an oligonucleotide sequence of the present invention, which is in turn, operably linked to a heterologous gene, such as the gene for the luciferase reporter molecule. "Promoter" refers to a DNA regulatory region capable of binding directly or indirectly to RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of the present invention, the promoter is bound at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter will be found a transcription initiation site (conveniently defined by mapping with S1 nuclease), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CCAT" boxes. Prokaryotic promoters contain -10 and -35 consensus sequences, which serve to initiate transcription and the transcript products contain Shine-Dalgarno sequences, which serve as ribosome binding sequences during translation initiation.

Recombinant host cell [0038] A host cell or indicator cell has been "transfected" by exogenous or heterologous DNA (e.g. a DNA construct) when such DNA has been introduced inside the cell. The transfecting DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transfecting DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transfected cell is one in which the transfecting DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transfecting DNA. Transfection methods are well known in the art (Sambrook et al., 1989, supra; Ausubel et aL, 1994 supra).

Method for identifying other cancer cells against which Cry3l Aa2 is c otoxic [0039] In addition to the EC50 assay described herein, other assays may be used to determine the effects of Cry31 Aa2 or other proteins encompassed by the present invention on human cancer cells. In particular, these effects may be observed by photonic microscopy. Furthermore, assays for detecting cytopathic effects can also be used for this purpose.

[0040] Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of preferred embodiments thereof, given by way of example only with reference to the accompanying drawings.

[0041] The present invention seeks to meet these needs and other needs.

[0042] The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS
In the appended drawings:

[0043] Figure 1 illustrates in panel A) a phase-contrast micrograph of a lysed culture of Bacillus thuringiensis strain M15; in panel B, a transmission electron micrograph of Bacillus thuringiensis strain M15 containing a spore and a tightly bound parasporal inclusion;

[0044] Figure 2 shows a SDS-PAGE analysis of the parasporal inclusion protein(s) of B. thuringiensis strain M15;

[0045] Figure 3 is the nucleotide sequence of the translated portion of the Cry3lAa2 gene (SEQ ID NO: 1);

[0046] Figure 4 is the deduced amino acid sequence of the Cry39Aa2 gene (SEQ ID NO: 2);

[0047] Figure 5 shows a comparison of the deduced amino acid sequences of Cry3lAa2 (SEQ ID NO:2) and Cry3lAal (SEQ ID NO:18). The capital letters and dotted lines under the amino acid sequence of Cry31Aa2 (SEQ ID NO:2) correspond to the difference and alignment gaps between the Cry3lAa2 (SEQ ID NO:2) and Cry3lAal (SEQ ID NO:18). The asterisks under the Cry3lAa2 sequence indicate the identities between Cry3lAa2 (SEQ ID
NO:2) and Cry31Aal (SEQ ID NO:18);

[0048] Figure 6 shows a restriction map of the recombinant plasmid pYCP31A2 containing the Cry31Aa2 gene;

[0049] Figure 7 shows a transmission electron micrograph of a B.
thuringiensis Cr{ B transformant expressing the Cry3lAa2 gene. S: spore; P:
parasporal inclusion; Magnification : 20,000 X;

[0050] Figure 8 shows a SDS-PAGE analysis of the parasporal inclusion protein from a B. thuringiensis transformant expressing the crystal protein gene Cry31 Aa2;

[0051] Figure 9 shows the nucleotide sequence (SEQ ID NO:16) and deduced amino acid sequence (SEQ ID NO:2) of the Cry31Aa2 gene along with features thereof; and [0052] Figure 10 shows the nucleotide sequence of the translated portion of the Cry31Aal gene (SEQ ID NO:17).

DESCRIPTION OF THE PREFERRED EMBODIMENT

Isolation of strain, morphological and biochemical characteristics [0053] A Bacillus thuringiensis strain was isolated from dead two-spotted spider mites (Tetranychus urticae Koch; Arthropoda: Arachnida: Tetranychidae) and named M15. The mites, parasitic on apple leaves, were collected in an apple orchard located in Frelighsburgh, Quebec, Canada. They were homogenized in 3 ml of phosphate-buffered saline (PBS) (NaCl 8 g, KCI 0.2 g, Na2HPO4 1.44 g, KH2PO4 0.24 g I-1). The homogenized solution was incubated for 16 hr at room temp and heated at 78 C for 15 min. Afterwards, the homogenate was plated on 2YT agar medium (Bacto Tryptone 16 g, Bacto Yeast Extract 10 g, NaCl 5 g, Agar 18 g I-1), and incubated for 24 hr at 30 C.
All colonies with a morphology similar to B. thuringiensis were streaked on T3 agar medium (Bacto Tryptone 3 g, Bacto Tryptose 2 g, Bacto Yeast Extract 1.5 g, MnC12 0.005 g, 0.05M Sodium phosphate, pH6.7, Agar 18 g I-1) and incubated at 30 C for 48 hr. The cultures were examined by phase-contrast microscopy (Carl Zeiss Canada Ltd., Toronto, Ontario, Canada) for the presence of spores and crystals. B. thuringiensis M15 was deposited on 29 January 2001 in the International Depository Authority of Health Canada in Winnipeg under the Budapest Treaty (Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, R3E 3R2) under accession no.
I DAC010201-5.

[0054] The M15 strain was characterized for its ability to ferment specific carbon sources, and for the production, utilization and reduction of specific compounds (see Table 1 below). The biochemical characteristics of B.
thuringiensis strain M15, obtained using the API 50CH and API 20E kits as recommended by the manufacturer (bioMerieux, St-Laurent, Quebec, Canada), were different from those of three controls, B. thuringiensis var. kurstaki HD-1, -var. israelensis HD-500 and -var. higo BT205. B. thuringiensis var. kurstaki HD-1 and -var. israelensis HD-500 were obtained from "Laboratoire des bacteries entomopathogenes", Institut Pasteur (Paris, France). B. thuringiensis var.
higo BT205 was in the Agriculture Canada collection (Jung et at., 1998). The M15 strain is further characterized in Jung, 2001.

Table 1. The biochemical profile of B. thuringiensis M15 and selected control strains Tests B. thuringiensis B. thuringiensis B. thuringiensis B. thuringiensis var. kurstaki HD-1 var. israelensis HD-500 var. higo BT M 15 Fermentatio n of Glycerol + + +
D-Arabinose - - - -L-Arabinose - - - -Ribose + + + +
D-Xylose - - - -L-Xylose - - - -D-Galactose - - - -D-Glucose + + + +
D-Fructose + + + +
D-Mannose - - - -L-Sorbose - - - -Inositol - - - -D-Mannitol - - - -D-Sorbitol - - - -N- + + + +
Acetylglucosa mine Arbutin + + + -Esculin + +
Salicin + - + +
D- + + + -Cellobiose D-Maltose + + + +
Lactose - - - -Melibiose - - - -Sucrose - - - -Trehalose + + + +
Starch - + + -Glycogen + + + -Gluconate + + -Production of Galactosida se Arginine + + + -dihydrolase Ornithine - - - -decarboxyla se Urease + - + +
Tryptophane - - - -deaminase Gelatinase + + + +
Oxidase + + + +
Catalase + + + +

Indole - - - -Acetoin + + + +

Citrate + - - -utilization Nitrate + - - -reduction +, -, and indicate positive, negative, and weak reactions, respectively.
Microscopic characterization of Cry31 Aa2 parasporal inclusion bodies [0055] The parasporal inclusion bodies produced by a sporulated culture of B. thuringiensis strain M15 appear roughly spherical when observed under phase-contrast microscopy (Fig. 1 A) and are tightly coupled to the spores even in lysed cultures. Further analysis under the transmission electron microscope (TEM), however, reveals that the parasporal inclusion body has a polygonal shape (Fig. 1B). The TEM observation was conducted after the B.
thuringiensis strain M15 was incubated for 5 days at 309C in T3 medium and the samples ultra-thinly sectioned according to Beveridge et al. (1994).
Arrows show the roughly spherical parasporal inclusions tightly bound to the white ovoid spores. In this figure, "S" and "P" denote spore and parasporal inclusion, respectively. Magnification used is of 25,000 X.

SDS-PAGE analysis and N-terminal sequencing of the native parasporal inclusion protein [0056] The B. thuringiensis strain M15 was grown in T3 medium for 5 days at 30 C on a rotary shaker to allow crystal protein production. Spores and crystals were separated from each other in the tightly bound parasporal duplexes using an ultrasonic processor model VC 130 (Sonics & Materials, Inc., Newtown, CT, USA) and purified by sucrose density gradient centrifugation as described elsewhere (Thomas and Ellar, 1983). Twenty microliters of the crystal suspension were added to 3 volumes of gel loading buffer (4% SDS, 20% glycerol, 125 mM Tris-HCI, 10% 2-mercaptoethanol, pH 6.8) in a 1.5-ml microtube, incubated at 90 C for 7 min and centrifuged for 2 min to remove unsolubilized materials. Thirty microliters of the supernatant were loaded on top of 10% SDS-polyacrylamide gels. Discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli and Favre (1973).

[0057] Figure 2 shows the B. thuringiensis strain M15 parasporal inclusion purified by sucrose density gradient centrifugation as subjected to a 10% SDS-PAGE electrophoresis (lane 4); the crude extracts of the fully lysed B. thuringiensis var. kurstaki HD-1 subjected to electrophoresis on the same gel (lane 3) as a control; and high molecular (lane 1) and low molecular masses (lane 2) of standard protein markers on the left. At least two major bands of approximately 86- and 79-KDa in size were revealed. They were transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-RadTM), excised and subjected to a pulsed liquid phase sequencer for determination of N-terminal amino acid sequence.

[0058] The N-terminal amino acid sequence of the crystal protein from B.
thuringiensis strain M15 was determined as follows. The purified parasporal crystal was added into O.1 N NaOH-3M HEPES solution and solubilized in 10 volumes of gel loading buffer by incubating in boiling water for 5 min. The crystal protein was separated on 10 % SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Mississauga, Ontario, Canada). The crystal protein band stained with Coomassie brilliant blueTM R-250 (Bio-Rad) was excised and subjected to a pulsed liquid phase sequencer model 473A (Applied Biosystems, Foster City, CA, USA) at the Regional Sequencing Facility (Centre de recherche du Centre hospitalier de I'Universite Laval, Quebec, Canada).

[0059] The N-terminal sequence analysis revealed that both polypeptides (86- and 79-KDa) shared identical 20-amino acids residues.
These were Met, Asp, Pro, Phe, Ser, Asn, Tyr, Ser, Glu, Gin, Lys, Tyr, Pro, Asp, Ser, Asn, Asn, Asn, Gin and Glu (SEQ ID NO: 3).

Southern hybridization and gene cloning [0060] An 18-mer oligonucleotide sequence, referred to as M15-M, was deduced from a middle portion of the N-terminal amino acid sequence (Glu, Gin, Lys, Tyr, Pro, Asp (SEQ ID NO: 4)) of the 86-kDa crystal protein. The M15-M oligonucleotide was labeled by the Digoxigenin (DIG) oligonucleotide 3'-end labeling kit containing DIG-11-ddUTP (Roche, Laval, Quebec, Canada) as recommended by the manufacturer. The labeled oligonucleotide was precipitated with 0.1 volume of 4M LiCI and 2.5 volumes of ice-cold ethanol, and transferred at -70 C for 30 min. The reaction was centrifuged at 16,000g for 15 min at 4 C. The washed pellet was resuspended in nuclease-free water, and stored at -20 C until use.

[0061] The M 15-M generated had the following sequence: 5'-GARCARAARTAYCCNGAY-3' (SEQ ID NO: 5).

[0062] B. thuringiensis strain M15 was grown in Luria-Bertani (LB) medium (Bacto Tryptone 10 g, Bacto Yeast Extract 5 g, NaCl 5 g I-1) at 30 C
for 16 hr on a rotary shaker. Plasmid DNA was isolated using the alkaline extraction method as described elsewhere (Birnboim and Doly, 1979) with the following modifications. LysozymeTM (Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada) was added at a concentration of 2 mg.ml-1 and the cell suspension was incubated at 37 C for 1 hr.

[0063] The plasmid DNA was then purified with Wizard TM Plus SV
minipreps DNA purification system following the manufacturer's recommendation (Promega, Nepean, Ontario, Canada). Three samples of the plasmid were then digested with Hindlll, HindlIl/EcoRl and EcoRl (Gibco BRL), respectively, electrophoresed on a 0.7% agarose gel and transferred onto a NytranTM nylon membrane (Schleicher & Schuell, Keene, New Hampshire, USA) by the method of Southern (1975). They were then probed with the DIG-labeled 18-mer M15-M oligonucleotide.

[0064] This Southern blot hybridization was performed using the DIG-labeled oligonucleotides with the standard hybridization solution (5X SSC, 1%
blocking reagent (Roche), 0.1% N-lauroylsarcosine, 0.02% SDS) for 13 hr at 39 C. After hybridization, the membrane was washed twice for 15 min each in 4X wash solution (4X SSC, 0.1% SDS) at 39 C. Following the washes, detection of signals on the membrane was performed with the color-substrate solution containing NBT (4-Nitroblue tetrazolium chloride, Roche) and BCIP (5-Bromo-4-chloro-3-indolyl-phosphate, Roche) as recommended by the manufacturer. After hybridization and post-hybridization washes at 39 C, the M15-M probe strongly hybridized to an 8-kb Hindlll, a 2.6-kb Hindlll/EcoRl, and a 2.6-kb EcoRl fragment.

[0065] The purified B. thuringiensis M15 plasmid DNA was digested with Hindlll and ligated with the Hind lll-digested SAP (Shrimp Alkaline Phosphatase, Roche)-treated pBluescriptTM II KS(+) (Stratagene, La Jolla, California, USA). After ligation, the recombinant DNA was transformed into E.
coli DH5a (Gibco BRL, Burlington, Ontario, Canada). Preparation of E. coli DH5a competent cells and transformation were done as described (Sambrook et al., 1989).

[0066] The transformants were grown on LB agar plates containing 100 g ml-1 ampicillin (Sigma-Aldrich Canada Ltd.) and 40 g ml-1 X-Gal (5'-Bromo-4-chloro-3-indolyl-p-D-galactopyranoside, Sigma-Aldrich Canada Ltd.) at 37 C. White colonies were toothpicks-transferred to 1 ml of fresh LB media supplemented with 100 .tg ml-1 ampicillin, and incubated overnight at 37 C.
[0067] The recombinant DNA were then isolated by the cracking procedure (Sambrook et al., 1989) and electrophoresed on 0.7% agarose gel to assess the size of the undigested recombinant plasmids.

[0068] The three recombinant plasmids with the highest molecular weight were selected and digested with Hindlll. They were designated pYCH27, pYCH40 and pYCH217, respectively. All three plasmids contained an 8-kb Hindlll insert. In addition, pYCH27 and pYCH40 also contained a 0.75-kb and a 1.9-kb Hindlll fragment, respectively. They were then electrophoresed on a 0.7% agarose gel, transferred onto a NytranTM nylon membrane by the method of Southern (1975) and probed with the M15-M oligonucleotide. The M15-M probe hybridized to the 8-kb Hindlll fragments in pYCH27, pYCH40 and pYCH217 as revealed by Southern blot hybridization.

[0069] The 8-kb Hindlll fragments from pYCH27, pYCH40 and pYCH217 were doubly digested with Hindlll/EcoRl, electrophoresed on agarose gel, Southern transferred, and hybridized with the M15-M probe. For each of the three recombinant plasmids, a single 2.6-kb fragment was detected (data not shown). This confirms that this 2.6-kb fragment is the same as the one in the EcoRl-digested plasmid DNA of strain M15.

[0070] The 8-kb Hindlll insert was excised from recombinant plasmid pYCH217, digested with various restriction enzymes [EcoRl, Bglll (Gibco BRL), Dral, Sphl (Amersham Pharmacia Biotech)], and a restriction map constructed.
The 8-kb Hindlll fragment contains a 3.4-kb HindlII/EcoRl, a 2.6-kb EcoRl/EcoRl, a 1.4-kb EcoRl/EcoRl and a 0.6-kb EcoRl/Hindlll fragment. The open reading frame of a crystal protein gene, cry3lAa2, is indicated by a gray arrow. The hatched box indicates the region homologous to the DIG-labeled 18-mer M15-M oligonucleotide probe. Selected subfragment sizes are indicated below the structural map.

[0071] To identify the region homologous to the M15-M probe, the recombinant plasmid pYCH217 was doubly digested with Hindlll/EcoRl, and the resulting fragments were subcloned into EcoRl-digested pBluescriptTM II
KS(+). After ligation, four subclones were obtained to give the recombinant plasmids pYC12S, pYC22S, pYC30S, and pYC31S. Plasmids pYC12S and pYC30S contained a 1.4-kb and a 2.6-kb insert, respectively, while pYC22S
and pYC31 S both harbored a 2.6-kb insert along with a 0.6-kb and a 1.4-kb fragment, respectively. Only the 2.6-kb EcoRl/EcoRl fragment from subclones, pYC22S, pYC30S and pYC31S hybridized with the M15-M probe. To further localize the region of hybridization of the M15-M probe in the 2.6-kb EcoRl/EcoRl fragment, the recombinant plasmid pYC30S was digested with EcoRl, EcoRl/Dral, EcoRI/Sphl, and EcoRl/BgllI, respectively, and then hybridized with the M15-M probe. The M15-M probe detected a 2.6-kb EcoRl, a 0.6-kb Dral, a 1.6-kb EcoRl/Sphl, and a 0.85-kb EcoRl/BgIII fragment, respectively. It was thus determined that the region of hybridization of the M probe lied between the BgIII and Dral sites within the 2.6-kb EcoRl fragment.
Characterization of a new crystal protein gene, cry31Aa2 [0072] The nucleotide sequences of the 2.6-kb EcoRI/EcoRl, 1.4-kb EcoRl/EcoRl and 0.6-kb EcoRl/Hindlll fragments were determined. An open reading frame (ORF) of 2,226-bp in length that codes for a polypeptide of 742 amino acids with a predicted molecular mass of 83,068Da (Figures 3 and 4) was found. The start codon is not ATG but GTG. One potential promoter-like sequence in the 5' non-coding region (Lereclus et al., 1989; Baum and Malvar, 1995) shows a 13-bp spacing between the putative -10 and -35 sequences located 138-bp upstream from the start codon (GTG). The potential ribosome binding site (RBS) (GAAAGGTGG (SEQ ID NO: 6)) is located 7-bp upstream of the start codon (GTG) and is partially complementary to the 3' end (UCUUUCCUCC (SEQ ID NO: 7)) of B. subtilis 16S rRNA (McLaughlin et al., 1981; Moran et al., 1982). Both potential -35 and -10 boxes and a putative ribosome-binding site are underlined in figure 9. The calculated free energy of interaction (AG, 25 C) between the B. subtilis 16S rRNA and the putative ribosome binding site is -14.8 kcal-mol-1 (Tinoco et al., 1973). A terminal inverted repeat that could form a stem-and-loop secondary structure with a calculated energy (AG, 25 C) of -12.2 kcal=mol-1 (Tinoco et al., 1973) is located 112-bp downstream from the stop codon (TAA), which is marked with asterisks in figure 9, and may function as a transcription terminator (indicated by arrows). The 18-mer M15-M oligonucleotide sequence based on the N-terminal amino acid sequence (Glu, Gin, Lys, Tyr, Pro, Asp (SEQ ID NO: 4)) of the crystal protein is homologous to a region located 24-bp downstream from the start codon (GTG). The sequence of the DIG-labeled 18-mer oligonucleotide (M15-M) probe is indicated in bold capital letters in figure 9.
The crv3lAa2 gene expression in B. thuringgiensis Cry- B strain [0073] The 3.6-kb Hindlll/Sphl fragment containing the entire crystal protein gene was excised from the recombinant plasmid pYCH217, and then cloned into the E. coli-B. thuringiensis shuttle vector pHPS9 doubly digested with Hindlll/Sphl to yield recombinant plasmid pYCP31A2 (Figure 6). The E.
coli-B. thuringiensis shuttle vector pHPS9 (Haima, et al., 1990) was purchased from American Type Culture Collection (Manassas, VA, USA). To express the cloned cry3lAa2 crystal protein gene in the acrystalliferous B. thuringiensis strain Cry- B, the 3.6-kb Hindlll/Sphl fragment was cloned into the Hindlll/Sphl doubly-digested E. coli-B. thuringiensis shuttle vector pHPS9 to yield recombinant plasmid pYCP31A2 (Fig. 6).

[0074] The B. thuringiensis var. kurstaki HD-1 acrystalliferous Cry-B
strain ((Stahly et al., 1978) provided by the Bacillus Genetic Stock Center, The Ohio State University (Columbus, OH, USA)), was transformed with the cloned B. thuringiensis M15 crystal protein gene by electroporation as described by Vehmaanpera (1989) with the following modifications. Bacterial cells cultured in 200 ml of LB supplemented with 0.25 M sucrose and 0.05 M potassium phosphate, pH7.0 (LBSP) to an optical density of 1.0 at 600 nm were centrifuged, washed three times with ice-cold SHMG buffer (250 mM sucrose, 1 mM HEPES, 1 mM MgC12, 10% (v/v) glycerol, pH 7.0), and then resuspended in 1 ml of ice-cold SHMG buffer. The cell suspension was mixed with plasmid DNA at a final DNA concentration of 10 g ml-1 in a 0.2-cm electroporation cuvette (Bio-Rad), kept on ice for 30 min, and then electroporated by a Gene PulserTM model 1652076 (Bio-Rad) at 25 F, 2.5kV and 400Q with the pulse once. After electroporation, 3ml of LBSP supplemented with 10% (v/v) glycerol (LBSPG) were immediately added into the cuvette and incubated at 37 C for 2 hr with shaking.

[0075] The selected B. thuringiensis transformant was cultured in 250 ml of nutrient broth supplemented with 5 gg m1-1 of erythromycin (Sigma-Aldrich Canada Ltd.) and 5 g ml-1 of chloramphenicol (Sigma-Aldrich Canada Ltd.) at 37 C until cell autolysis was observed. The lysate was harvested and then washed twice with 10 mM EDTA (pH 8.0)-1 M NaCI-1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich Canada Ltd.).

[0076] The B. thuringiensis Cry- B transformant containing the B.
thuringiensis M15 parasporal crystal protein gene was incubated in nutrient broth (Bacto Beef Extract 3 g, Bacto Peptone 5 g I-1) at 30 C for 3 days to allow expression of the toxin gene and crystal formation. The presence of parasporal inclusions was examined by phase-contrast microscopy. When observed under a phase-contrast microscope, the B. thuringiensis transformants expressing the cry31 Aa2 gene contained, in addition to the spore, a roughly spherical inclusion, whereas no inclusions were found in the B.
thuringiensis transformant harboring the non-recombinant shuttle vector pHPS9 alone (data not shown). Under the transmission electron microscope (TEM), however, the parasporal inclusion body has a nearly perfect hexagonal shape (Fig. 7). Both inclusions in the transformant, spore and crystal, are separated from each other as opposed to what is found in B. thuringiensis strain M15 where they are tightly bound to each other.

[0077] The parasporal inclusion from a B. thuringiensis transformant was purified by sucrose density gradient centrifugation as described previously (Thomas and Ellar, 1983). It was then subjected to a 10% discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SIDS-PAGE) (lane 3) as reported previously (Laemmli and Favre, 1973). High molecular (lane 1) and low molecular masses (lane 2) of standard protein markers are indicated on the left. The parasporal inclusion protein in the B. thuringiensis transformant is composed of a single major polypeptide of 83-kDa (Fig. 8).

Preparation of inclusion proteins, proteolytic processing, and toxin activation [0078] The spore-inclusion mixture was harvested from sporulated cultures and the inclusions were partially purified by a biphasic separation method described in Goodman (1967) using polyethylene glycol 6000 (Wako Pure Chemical, Osaka, Japan) and sodium dextran sulfate 500 (Sigma, St.
Louis, Mo.). Inclusions were further purified by sucrose density gradient centrifugation as described in Saitoh et al., (1998a). The purified inclusions were stored at 20 C until use.

[0079] Solubilization of purified inclusions was done in 50 mM Na2CO3 (pH 10.0) containing 1 mM EDTA and 10 mM dithiothreitol for 1 h at 37 C. After centrifugation at 20,000 x g for 5 min at 4 C to remove unsolubilized materials, the pH of the solution was adjusted to 8Ø

[0080] The native 83KDa protoxine displayed no cytocidal activity against cancer cells. This protein was therefore cleaved with three enzymes, namely trypsin, chymotrypsin and proteinase K to identify an active toxine.
The solubilized proteins (1.3 mg m11) were therefore treated with proteinase K
(final concentrations, 0.0003, 0.003, 0.03, and 0.3 mg m11), trypsin (0.03, 0.3, 3, and 30 mg m11), and chymotrypsin (0.03, 0.3, 3, and 30 mg m11) in 50 mM Na2CO3 (pH 10.0) for 1.5 h at 37 C. After protease treatment, phenylmethylsulfonyl fluoride (Wako Pure Chemical) was added to the solution to stop the proteolytic reaction, and the mixture was examined for both sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) profiles and cytopathic effect (CPE) on certain cancer cells including MOLT-4 and Hela. The CPE was monitored under a phase-contrast microscope for 24 h, and the degree of cytopathy was graded on the basis of the ratio of damaged cells as described in Mizuki et al., (1999).

One-dose assay, hemolytic assay, and dose-response study [0081] One-dose assays for cytotoxicity and hemolytic activity were carried out as described in Mizuki et al., (1999). Each well of a MicroTest plate received 90 pl of cell suspension containing 2 x 104 cells. After preincubation for 16 h at 37 C, 10 pI of the trypsin-activated sample solution (1.3 mg ml) was added to the well.

[0082] Thirteen human cells, two monkey cells and one mouse cell were used for dose-response studies. A hemolytic assay was done using human erythrocytes according to the method described in Saitoh et al., (1998b). Each well containing 90 1u1 of cell suspension (2 x 104 cells) received 10 N1 of trypsin-activated inclusion proteins which had been prepared in 10-fold serial dilutions in 50 mM Na2CO3 (pH 10.0) containing 10 mM DTT and 1 mM EDTA. Five wells were used for each dilution, and the test was repeated at least three times. The CPE was monitored under a phase-contrast microscope at appropriate intervals for 24 h postinoculation.

[0083] For assessment of the level of cytotoxicity, a cell proliferation test using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide] assay as described in Behl (1992) and Heiss (1997) was conducted 24 h postinoculation by using a PremixTM WST-1 kit (Takara Co.). The average of absorbance in mock-inoculated negative controls was used as a blank value.
The arbitrary unit was defined on the basis of the relative value of absorbance at 450 nm to the blank (1.0). The 50% effective concentrations (EC50s) were deduced from the dose-response curves using a log-probit program. Table 2 below presents the EC50s.

[0084] The protein exhibited cytotoxicity against HeLa, TCS, HL-60, Jurkat and Hep-G2 cells when treated with trypsin. No cytocidal activity was induced after treatment with chymotrypsin or proteinase K on HeLa, MOLT-4 and Sawano cells. Without protease digestion, inclusion proteins showed no cytocidal toxicity. Trypsin cleaves the cry31 Aa2 protein after the arginine at position 250 of the full native protein sequence (SEQ ID NO: 2). The sequence of the trypsin-activated protein is designated SEQ ID NO: 8 and the corresponding nucleotide sequence is designated SEQ ID NO: 9.

[0085] Table 2 shows the results of one-dose assays of trypsin-activated Cry31 Aa2 as compared to those of trypsin-activated Cry3lAal against several species of cultured cells. The toxicity spectrum of the protein from the recombinant Cry-B was similar to that of the protein of the wild strain M15.
Both cloned proteins were highly or moderately cytocidal against HeLa, TCS, HL-60, Jurkat and Hep-G2 but were slightly toxic or nontoxic for normal T
cells and for Sawano, UtSMC, MOLT-4, A549, MRC-5, HC, Caco-2 and the non human cells tested.

Table 2 Effective concentration 50 of trypsin-activated cry31Aa2 as compared to that of activated cry31Aa 1 on various cells EC50(ug/ml) EC50(ug/ml) Organ Cell Cell type Cry3lAa2 Cry3lAal 1 Human Uterus HeLa Cervix cancer 0.30 0.23 2 Sawano Uterus cancer, adenocarcinoma >10 3 TCS Cervix cancer, keratinizing squamous 0.32 4 UtSMC Uterus normal smooth muscle >10 5 Blood MOLT-4 T cell leukaemia >10 1.06 6 HL-60 T cell leukaemia 0.05 7 Jurkat T cell leukaemia 0.02 8 T cell Normal T cell >10 9 Lung A549 Lung cancer >10 10 MRC-5 Lung normal fibroblast >10 11 Liver HC Normal hepatocyte cell >10 12 Hep-G2 Liver carcinoma hepatocellular 0.02 13 Colon Caco-2 fColon cancer, adenocarcinoma >10 14 Monkey Kidney Vero Monkey, kidney epithelial cell >10 15 COS-7 Monkey, kidney SV40 transformed cell >10 16 Mouse Embryo NIH3T3 Mouse, embryo fibroblast cell >10 Comparison of Cry3lAa2 and Cry31Aal [0001] As may be seen in Figure 5, the Cry3lAa2 amino acid sequence shares extensive homology with Cry31Aal except for a substitution of 26 amino acid residues and an addition of 19 contiguous codons in Cry31Aa2 (Figure 5). This 19 amino acid sequence is as follows SYQNMKTEIVNTDLPYNTN and is designated SEQ ID NO: 10 while the corresponding nucleotide sequence is designated SEQ ID NO: 11. The asterisks under the Cry3lAa2 sequence indicate the identities between Cry31Aa2 and Cry3lAal. The capital letters and dotted lines under the amino acid sequence of Cry3lAa2 in Figure 5, correspond to the difference and alignment gaps between the Cry31Aa2 and Cry3lAal proteins. The 83-KDa Cry3lAa2 protein exhibits 93.9% amino acid sequence identities with the Cry3lAal protein. The five conserved amino acid blocks of the Cry3lAa2 protein were especially identical to those of the Cry3lAal protein except for the substitution of a single lysine residue in the second conserved block of Cry3lAa2. The bold lines above the Cry3lAa2 sequence correspond to the five conserved amino acid blocks found in the amino acid sequence of Cry3lAal.
Both Cry3lAa2 and Cry3lAal show very low amino acid sequence homology to the known B. thuringiensis Cry and Cyt proteins (Mizuki et al., 2000). The trypsin-activated protein shares a 96.9% identity with the corresponding sequence of Cry3lAal.

[0002] Table 2 above shows that both Cry3lAa2 and Cry3lAal proteins display cytotoxicity against a number of human cancer cells. The cytocidal activity of the Cry3lAal was due to the cleavage by proteinase K and trypsin (Mizuki et al., 2000) while that of Cry3lAa2 was due to trypsin. The comparison of the amino acid sequence of Cry3lAal with that of Cry3lAa2 indicates which amino acids of the amino acid sequence of members of the Cry3l family can be substituted without abrogating this cytoxicity against human cancer cells.
Although certain of these substitutions surely provide for the specificity of each of Cry3lAa2 and Cry3lAal against specific human cancer cells, they each display a significant toxicity against a number of human cancer cells. Hence, it is submitted that the amino acids at positions 24, 37, 39, 51, 56, 59, 87, 97, 138, 158, 170, 251, 389, 444-446, 466, 481, 507, 510, 518, 551, 582, 637, 725 and 742 can be replaced by any other amino acid without abrogating the cytotoxicity of the protein that it constitutes against at least some cancer cells.
Sequences encompassing substitutions at these positions in the complete Cry31Aa2 protein sequence (SEQ ID NO:2) and in the trypsin-activated Cry3lAa2 protein sequence (SEQ ID NO:8) starting after the arginine at position 250 are within the scope of the present invention and are designated herein as SEQ ID NOs:12 and 13, respectively.

[0088] Certain substitutions are preferred however and correspond to either a substitution by an amino acid having similar chemical properties or, even more preferred, a substitution by the amino acid found at the corresponding position in Cry3lAal. Amino acids are categorized herein into 5 groups of amino acids according to their chemical properties, namely small nonpolar (i.e. C, P, A and T), small polar (i.e. S, G, D and N), large polar (i.e. E, 0, K and R), intermediate polarity (i.e. Y, H and W), aand large nonpolar (i.e. F, M, L, I and V) . Hence, the amino acid at position 24 of the Cry31 Aa2, is preferably a polar amino acid, most preferably a large polar amino acid and even more preferably glutamate or lysine. The amino acid at position 37 is preferably methionine or alanine. The amino acid at position 39 is preferably threonine or asparagine. The amino acid at position 51, is preferably a nonpolar amino acid, most preferably a small nonpolar amino acid and even more preferably alanine or threonine. The amino acid at position 56 is preferably proline or serine. The amino acid at position 59 is preferably an amino acid of intermediate polarity and most preferably tyrosine or tryptophan. The amino acid at position 87, is preferably a polar amino acid, most preferably a small polar amino acid and even more preferably asparagine or aspartate. The amino acid at position 97, is preferably a polar amino acid, most preferably a large polar amino acid and even most preferably arginine or lysine. The amino acid at position 138 is preferably a polar amino acid, most preferably a large polar amino acid and even more preferably glutamate or lysine. The amino acid at position 158 is preferably alanine or asparagine. The amino acid at position is preferably a polar amino acid, most preferably a small polar amino acid and even more preferably glycine or serine.

[0089] The amino acid at position 251 is preferably a nonpolar amino acid, most preferably a large nonpolar amino acid and even more preferably isoleucine or methionine. The amino acid at position 389 is preferably a polar amino acid, most preferably a large polar amino acid and even more preferably lysine or arginine. The amino acid at position 444 is preferably serine or histidine. The amino acid at position 445 is preferably a polar amino acid, most preferably a small polar amino acid and even more preferably glycine or serine.
The amino acid at position 446 is preferably glycine or proline. The amino acid at position 466 is preferably a polar amino acid, most preferably a large polar amino acid and even more preferably glutamine or arginine. The amino acid at position 481 is preferably an amino acid of intermediate polarity and most preferably tyrosine or tryptophan. The amino acid at position 507 is preferably alanine or leucine. The amino acid at position 510 is preferably glycine or histidine. The amino acid at position 518 is preferably a nonpolar amino acid and is preferably alanine or valine. The amino acid at position 551 is preferably a nonpolar amino acid, most preferably a small nonpolar amino acid and even more preferably alanine or proline. The amino acid at position 582 is preferably a nonpolar amino acid, most preferably a small nonpolar amino acid and even more preferably alanine or threonine. The amino acid at position 637 is preferably arginine or isoleucine. The amino acid at position 725 is preferably glycine or arginine. Finally, the amino acid at position 742 is preferably valine or serine. Sequences encompassing the most preferred substitutions listed above at these positions in the complete Cry3lAa2 protein sequence (SEQ ID NO:2) and in the trypsin-activated Cry3lAa2 protein sequence (SEQ ID NO:8) starting after the arginine at position 250 are within the scope of the present invention and are designated herein as SEQ ID NOs:14 and 15, respectively.

[0090] Sequences encompassing all the possible substitutions to the cry3lAa2 gene nucleotide sequence, the crystal protein and the trypsin-activated crystal protein derived from the crystal protein of the Bacillus thuringiensis M15 deposited under no. IDAC010201-5 as described above are within the scope of the present invention.

[0091] Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims.

REFERENCES
1. Aronson, A. (1993). The two faces of Bacillus thuringiensis: insecticidal proteins and post-exponential survival. Mol. Microbiol. 7, 489-496.

2. Baum, J. A., and Malvar, T. (1995). Regulation of insecticidal crystal protein production in Bacillus thuringiensis. Mol. Micro biol. 18, 1-12.

3. Behl, C., J. Davis, G. M. Cole, and D. Schubert. 1992. Vitamin E protects nerve cells from amyloid protein toxicity. Biochem. Biophys. Res. Commun.
186:944-950.

4. Beveridge, T. J., Popkin, T. J., and Cole, R. M. (1994). Electron microscopy. In "Methods for General and Molecular Bacteriology"
(Gerhardt, P., R. G. E. Murray, W. A. Wood, and N. R. Krieg, Eds.), pp.
42-71. Washington, D.C. Am. Soc. for Microbiol.

5. Birnboim, H. C., and Doly, J. (1979). A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7, 1513-1523.

6. Crickmore, N. 2001. Bacillus thuringiensis toxin gene nomenclature. Web site http://epunix. biols. susx. ac. uk/Home/Neii_Crickmore/Bt/index.html.
7. Crickmore, N., Zeigler, D. R., Feitelson, J., Schnepf, E., Van Rie, J., Lereclus, D., Baum, J., and Dean, D. H. (1998). Revision of the nomenclature for the Bacillus thuringiensis pesticidal crystal proteins.
Microbiol. Mol. Biol. Rev. 62, 807-813. de Barjac, H., and Frachon, E.
(1990). Classification of Bacillus thuringiensis strains. Entomophaga 35, 233-240.

8. Feitelson, J. S., Payne, J., and Kim, L. (1992). Bacillus thuringiensis:
insects and beyond. Bio/Technology 10, 271-275.

9. Gill, S. S., Cowles, E. A., and Pietrantonio, P. V. (1992). The mode of action of B. thuringiensis endotoxins. Annu. Rev. Entomol. 37, 615-636.
10. Goodman, N. S., R. J. Gottfried, and M. H. Rogoff. 1967. Biphasic system for separation of spores and crystals of Bacillus thuringiensis. J. Bacteriol.
94:485 11.Haima, P., Van Sinderen, D., Schotting, H., Bron, S., and Venema, G.
(1990). Development of a P-galactosidase a-complementation system for molecular cloning in Bacillus subtilis. Gene 86, 63-69.

12. Heiss, P., S. Bernatz, G. Bruchelt, and R. Senekowitsch-Schmidtke. 1997.
Cytotoxic effect of immunoconjugate composed of glucose-oxidase coupled to an anti-ganglioside (GD2) antibody on spheroids. Anticancer Res.
17:3177-3178 13. Hofte, H., and Whiteley, H. R. (1989). Insecticidal crystal proteins of B.
thuringiensis. Micro biol. Rev. 53, 242-255.

14. Jung, Y. C., Kim, S. U., Cote, J. -C., Lecadet, M. -M., and Chung, Y. S., and Bok, S. H. (1998). Characterization of a new Bacillus thuringiensis subsp. higo strain isolated from rice bran in Korea. J. lnvertebr. Pathol.
71, 95-96.

15. Kim, H. S. (2000). Comparative study of the frequency, flagellar serotype, crystal shape, toxicity, and cry gene contents of Bacillus thuringiensis from three environments. Curr. Microbiol. 41, 250-256.

16.Laemmli, U. K., and Favre, M. (1973). Maturation of the head of acteriophage T4. J. Mol. Biol. 80, 575-599.

17.Lecadet, M. -M., Frachon, E., Cosmao Dumanoir, V. et at. (1999).
Updating the H-antigen classification of Bacillus thuringiensis. J. App!.
Microbiol. 86, 660-672.

18. Lee, D. W., Akao, T., Yamashita, S., Katayama, H., Maeda, M., Saitoh, H., Mizuki, E., and Ohba, M. (2000). Noninsecticidal parasporal proteins of a Bacillus thuringiensis serovar shandongiensis isolate exhibit a preferential cytotoxicity against human leukemic T cells. Biochem. Biophys. Res.
Commun. 272, 218-223.

19. Lereclus, D., Bourgouin, C., Lecadet, M. -M., Klier, A., and Rapoport, G.
(1989). Role, structure, and molecular organization of the genes coding for the parasporal 6-endotoxins of B. thuringiensis. In "Regulation of Procaryotic Development: Structural and Functional Analysis of Bacterial Sporulation and Germination" (Smith, I., R. A. Slepecky, and P. Setlow, Eds.), pp. 255-276, Washington, D.C. Am. Soc. for Microbiol.

20. McLaughlin, J. R., Murray, C. L., and Rabinowitz, J. C. (1981). Unique features in the ribosome binding site sequence of the Gram-positive Staphylococcus aureus 13-lactamase gene. J. Biol. Chem. 256, 11283-11291.

21.Mizuki, E., Ohba, M., Akao, T., Yamashita, S., Saitoh, H., and Park, Y. S.
(1999). Unique activity associated with non-insecticidal Bacillus thuringiensis parasporal inclusions: in vitro cell-killing action on human cancer cells. J. App!. Micro biol. 86, 477-486.

22. Mizuki, E., Park, Y. S., Saitoh, H., Yamashita, S., Akao, T., Higuchi, K., and Ohba, M. (2000). Parasporin, a human leukemic cell-recognizing parasporal protein of Bacillus thuringiensis. Clin. Diag. Lab. Immunol. 7, 625-634.

23. Moran, C. P., Lang, N., Jr., LeGrice, S. F. J., Lee, G., Stephens, M., Sonenshein, A. L., Pero, J., and Losick, R. (1982). Nucleotide sequences that signal the initiation of transcription and translation in Bacillus subtilis.
Mol Gen. Gene. 186, 339-346.

24.Ohba, M. (1996). Bacillus thuringiensis populations naturally occuring on mulberry leaves: a possible source of the populations associated with silkworm-rearing insectaries. J. Appl. Bacteriol. 80, 56-64.

25.Ohba, M., and Aizawa, K. (1986). Insect toxicity of Bacillus thuringiensis isolated from soils of Japan. J. Invertebr. Pathol. 47, 12-20.

26. Roh, J. Y., Park, H. W., Jin, B. R., Kim, H. S., Yu, Y. M., and Kang, S.
K.
(1996). Characterization of novel non-toxic Bacillus thuringiensis isolates from Korea. Lett. Appl. Microbiol. 23, 249-252.

27. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). "Molecular cloning.
A Laboratory manual," 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

28.Saitoh, H., K. Higuchi, E. Mizuki, and M. Ohba. (1998a). Larvicidal toxicity of Japanese Bacillus thuringiensis against the mosquito Anopheles stephensi.
Med. Vet. Entomol. 12:98-102.

29.Saitoh, H., K. Higuchi, E. Mizuki, S.-H. Hwang, and M. Ohba. (1998b).
Characterization of mosquito larvicidal parasporal inclusions of a Bacillus thuringiensis serovar higo strain. J. Appl. Microbiol. 84:883-888 30.Schnepf, H. E., Wong, H. C., and Whiteley, H. R. (1985). The amino acid sequence of a crystal protein from Bacillus thuringiensis deduced from the DNA base sequence. J. Biol. Chem. 260, 6264-6272.

31. Southern, E. (1975). Detection of specific sequences among DNA
fragments separated by gel electrophoresis. J. Mol. Biol. 98, 503-517.
32.Stahly, D. P., Dingman, D. W., Bulla, L. A., Jr., and Aronson, A. I.
(1978).
Possible origin and function of the parasporal crystal in Bacillus thuringiensis. Biochem. Biophys. Res. Commun. 84, 581-588.

33. Thomas, W. E., and Ellar, D. J. (1983). B. thuringiensis var. israelensis crystal S-endotoxin: effects on insect and mammalian cells in vitro and in vivo. J. Cell. Sci. 60, 181-197.

34.Tinoco, I., Jr., Borer, P. N., Dengler, B., Levine, M. D., Uhlenbeck, 0.
C., Crothers, D. M., and Gralla, J. (1973). Improved estimation of secondary structure in ribonucleic acids. Nature New Biol. 246, 40-41.

35.Vehmaanpera, J. (1989). Transformation of Bacillus amyloliquefaciens by electroporation. FEMS Microbiol. Lett. 61, 165-170.

36. Jung, Y.-C. (2001) Bacillus thuringiensis Strain M15, a Novel Autoagglutinable, Non-Serotypeable Strain-Cloning and Characterization of a Novel cry31A-type Crystal Protein Gene, cry3lAa2, and Two New Insertion Sequences, IS231M and -N. Departement de sciences biologiques, Faculte des arts et des sciences, Universite de Montreal.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: AGRICULTURE AGROALIMENTAIRE CANADA

(ii) TITLE OF INVENTION: A Novel Bacillus Thuringiensis Strain, Crystal Gene and Crystal Protein and Uses Thereof (iii) NUMBER OF SEQUENCES: 18 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Goudreau Gage Dubuc (B) STREET: Stock Exchange Tower suite 3400, 800 Place Victoria (C) CITY: Montreal (D) STATE: Quebec (E) COUNTRY: Canada (F) ZIP: H4Z 1E9 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: CA 2,410,153 (B) FILING DATE: 05-DEC-2002 (C) CLASSIFICATION: C12N-15/31 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Gauvreau, Julie (B) REGISTRATION NUMBER: 11,127 (C) REFERENCE/DOCKET NUMBER: 12292.5 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 514 397-7602 (B) TELEFAX: 514 397-4382 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2229 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 742 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asp Pro Phe Ser Asn Tyr Ser Glu Gln Lys Tyr Pro Asp Ser Asn Asn Asn Gln Glu Leu Ile Thr Glu Ser Ser Ser Phe Tyr Ser Asp Thr Thr Asn Glu Asn Met Lys Thr Tyr His Pro Ile Glu Gln Asp Ile Leu Lys Phe Ala Asn Gln Glu Phe Pro Asp Asn Tyr Tyr Gln His Ser Asp Val Ser Asn Ser Tyr Gln Asn Met Lys Thr Glu Ile Val Asn Thr Asp Leu Pro Tyr Asn Thr Asn Asn Ile Asn Ser Met Arg Asn Thr Leu Cys Arg Asp Leu Pro Pro Glu Thr Asn Met Ser Ile Tyr Asp Asn Leu Arg Ser Thr Val Thr Val Pro Ser Phe Ser Asn Gln Phe Asp Pro Ile Lys Phe Leu His Asp Ile Glu Ile Ala Ile Glu Thr Gly Ser Phe Ser Ala Leu Thr Gln Ser Asn Met Asn Gln Gly Gly Thr Asp Ile Ala Pro Met Leu Ile Ser Thr Phe Phe Lys Val Ala Gly Ser Leu Leu Pro Phe Pro Leu Ser Ser Leu Gly Ala Leu Ala Ser Phe Tyr Val Thr Asp Ser Gln Thr Gly Ala Met Ala Asn Leu Trp Arg Gln Met Val Asp Tyr Val Glu Lys Arg Ile Asp Ser Lys Ile Leu Asp Tyr His Asn Phe Ile Met Gly Ala Glu Leu Ala Ala Leu Asn Ala Ser Leu Lys Glu Tyr Ala Arg Val Val Lys Ile Phe Glu Asn Asp Met Asn Arg Ile Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Lys Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp Ser Gly Pro Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Gln Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Trp Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Ala Ala Trp His Met Trp Ser Ser Asp Pro Ser Ala Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Ala Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Ala Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Arg Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Gly Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Val (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Asp Pro Phe Ser Asn Tyr Ser Glu Gln Lys Tyr Pro Asp Ser Asn Asn Asn Gln Glu (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Glu Gln Lys Tyr Pro Asp (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (ix) FEATURE:
(A) NAME/KEY: misc feature (B) LOCATION: 15 (D) OTHER INFORMATION: /note= "N IS A, C, G, OR T"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: RNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus subtilis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 492 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ile Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Lys Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp Ser Gly Pro Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Gln Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Trp Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Ala Ala Trp His Met Trp Ser Ser Asp Pro Ser Ala Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Ala Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Ala Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Arg Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Gly Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Val (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1479 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ser Tyr Gln Asn Met Lys Thr Glu Ile Val Asn Thr Asp Leu Pro Tyr Asn Thr Asn (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 742 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 24 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 37 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 39 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 51 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 56 (D) OTHER INFORMATION: /note= "Xaa=anyt amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 59 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 87 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 97 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 138 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 158 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 170 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 251 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 389 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 444 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 445 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 446 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 466 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE :
(A) NAME/KEY: Modified-site (B) LOCATION: 481 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 507 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 510 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 518 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 551 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 582 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 637 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 725 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 742 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Asp Pro Phe Ser Asn Tyr Ser Glu Gln Lys Tyr Pro Asp Ser Asn Asn Asn Gln Glu Leu Ile Thr Xaa Ser Ser Ser Phe Tyr Ser Asp Thr Thr Asn Glu Asn Xaa Lys Xaa Tyr His Pro Ile Glu Gln Asp Ile Leu Lys Phe Xaa Asn Gln Glu Phe Xaa Asp Asn Xaa Tyr Gln His Ser Asp Val Ser Asn Ser Tyr Gln Asn Met Lys Thr Glu Ile Val Asn Thr Asp Leu Pro Tyr Asn Thr Asn Xaa Ile Asn Ser Met Arg Asn Thr Leu Cys Xaa Asp Leu Pro Pro Glu Thr Asn Met Ser Ile Tyr Asp Asn Leu Arg Ser Thr Val Thr Val Pro Ser Phe Ser Asn Gln Phe Asp Pro Ile Lys Phe Leu His Asp Ile Glu Ile Ala Ile Xaa Thr Gly Ser Phe Ser Ala Leu Thr Gln Ser Asn Met Asn Gln Gly Gly Thr Asp Ile Xaa Pro Met Leu Ile Ser Thr Phe Phe Lys Val Ala Xaa Ser Leu Leu Pro Phe Pro Leu Ser Ser Leu Gly Ala Leu Ala Ser Phe Tyr Val Thr Asp Ser Gln Thr Gly Ala Met Ala Asn Leu Trp Arg Gln Met Val Asp Tyr Val Glu Lys Arg Ile Asp Ser Lys Ile Leu Asp Tyr His Asn Phe Ile Met Gly Ala Glu Leu Ala Ala Leu Asn Ala Ser Leu Lys Glu Tyr Ala Arg Val Val Lys Ile Phe Glu Asn Asp Met Asn Arg Xaa Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Xaa Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp Xaa Xaa Xaa Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Xaa Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Xaa Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Xaa Ala Trp Xaa Met Trp Ser Ser Asp Pro Ser Xaa Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Xaa Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Xaa Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Xaa Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Xaa Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Xaa (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 492 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 139 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 194 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 195..196 (D) OTHER INFORMATION: /note= "Xaa can be any naturally occurring amino acid"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 216 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 231 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 257 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 260 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 268 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 301 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 332 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 387 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 475 (D) OTHER INFORMATION: /note= "Xaa= any amino acid"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 492 (D) OTHER INFORMATION: /note= "Xaa=any amino acid"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Xaa Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Xaa Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp Xaa Xaa Xaa Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Xaa Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Xaa Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Xaa Ala Trp Xaa Met Trp Ser Ser Asp Pro Ser Xaa Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Xaa Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Xaa Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Xaa Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Xaa Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Xaa (2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 742 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 24 (D) OTHER INFORMATION: /note= "Xaa=glutamate or lysine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 37 (D) OTHER INFORMATION: /note= "Xaa= methionine or alanine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 39 (D) OTHER INFORMATION: /note= "Xaa=threonine or asparagine"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 51 (D) OTHER INFORMATION: /note= "Xaa=alanine or threonine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 56 (D) OTHER INFORMATION: /note= "Xaa= proline or serine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 59 (D) OTHER INFORMATION: /note= "Xaa=tyrosine or tryptophan"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 87 (D) OTHER INFORMATION: /note= "Xaa= asparagine or aspartate"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 97 (D) OTHER INFORMATION: /note= "Xaa=arginine or lysine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 138 (D) OTHER INFORMATION: /note= "Xaa= glutamate or lysine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 158 (D) OTHER INFORMATION: /note= "Xaa= alanine or asparagine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 170 (D) OTHER INFORMATION: /note= "Xaa=glycine or serine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 251 (D) OTHER INFORMATION: /note= "Xaa= isoleucine or methionine"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 389 (D) OTHER INFORMATION: /note= "Xaa= lysine or arginine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 444 (D) OTHER INFORMATION: /note= "Xaa= serine or histidine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 445 (D) OTHER INFORMATION: /note= "Xaa= glycine or serine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 446 (D) OTHER INFORMATION: /note= "Xaa= glycine or proline"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 466 (D) OTHER INFORMATION: /note= "Xaa= glutamine or arginine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 481 (D) OTHER INFORMATION: /note= "Xaa= tyrosine or tryptophan"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 507 (D) OTHER INFORMATION: /note= "Xaa= alanine or leucine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 510 (D) OTHER INFORMATION: /note= "Xaa= glycine or histidine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 518 (D) OTHER INFORMATION: /note= "Xaa= alanine or valine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 551 (D) OTHER INFORMATION: /note= "Xaa= alanine or proline"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 582 (D) OTHER INFORMATION: /note= "Xaa= alanine or threonine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 637 (D) OTHER INFORMATION: /note= "Xaa= arginine or isoleucine"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 725 (D) OTHER INFORMATION: /note= "Xaa= glycine or arginine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 742 (D) OTHER INFORMATION: /note= "Xaa= valine or serine"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Asp Pro Phe Ser Asn Tyr Ser Glu Gln Lys Tyr Pro Asp Ser Asn Asn Asn Gln Glu Leu Ile Thr Xaa Ser Ser Ser Phe Tyr Ser Asp Thr Thr Asn Glu Asn Xaa Lys Xaa Tyr His Pro Ile Glu Gln Asp Ile Leu Lys Phe Xaa Asn Gln Glu Phe Xaa Asp Asn Xaa Tyr Gln His Ser Asp Val Ser Asn Ser Tyr Gln Asn Met Lys Thr Glu Ile Val Asn Thr Asp Leu Pro Tyr Asn Thr Asn Xaa Ile Asn Ser Met Arg Asn Thr Leu Cys Xaa Asp Leu Pro Pro Glu Thr Asn Met Ser Ile Tyr Asp Asn Leu Arg Ser Thr Val Thr Val Pro Ser Phe Ser Asn Gln Phe Asp Pro Ile Lys Phe Leu His Asp Ile Glu Ile Ala Ile Xaa Thr Gly Ser Phe Ser Ala Leu Thr Gln Ser Asn Met Asn Gln Gly Gly Thr Asp Ile Xaa Pro Met Leu Ile Ser Thr Phe Phe Lys Val Ala Xaa Ser Leu Leu Pro Phe Pro Leu Ser Ser Leu Gly Ala Leu Ala Ser Phe Tyr Val Thr Asp Ser Gln Thr Gly Ala Met Ala Asn Leu Trp Arg Gln Met Val Asp Tyr Val Glu Lys Arg Ile Asp Ser Lys Ile Leu Asp Tyr His Asn Phe Ile Met Gly Ala Glu Leu Ala Ala Leu Asn Ala Ser Leu Lys Glu Tyr Ala Arg Val Val Lys Ile Phe Glu Asn Asp Met Asn Arg Xaa Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Xaa Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp Xaa Xaa Xaa Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Xaa Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Xaa Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Xaa Ala Trp Xaa Met Trp Ser Ser Asp Pro Ser Xaa Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Xaa Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Xaa Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Xaa Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Xaa Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Xaa (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 492 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /note= "Xaa= isoleucine or methionine"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 139 (D) OTHER INFORMATION: /note= "Xaa= lysine or arginine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 194 (D) OTHER INFORMATION: /note= "Xaa= serine or histidine"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 195 (D) OTHER INFORMATION: /note= "Xaa= glycine or serine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 196 (D) OTHER INFORMATION: /note= "Xaa= glycine or proline"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 216 (D) OTHER INFORMATION: /note= "Xaa= glutamine or arginine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 231 (D) OTHER INFORMATION: /note= "Xaa= tyrosine or tryptophan"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 257 (D) OTHER INFORMATION: /note= "Xaa= alanine or leucine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 260 (D) OTHER INFORMATION: /note= "Xaa= glycine or histidine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 268 (D) OTHER INFORMATION: /note= "xaa= alanine or valine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 301 (D) OTHER INFORMATION: /note= "Xaa= alanine or proline"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 332 (D) OTHER INFORMATION: /note= "Xaa= alanine or threonine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 387 (D) OTHER INFORMATION: /note= "Xaa= arginine or isoleucine"

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 475 (D) OTHER INFORMATION: /note= "Xaa= glycine or arginine"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 492 (D) OTHER INFORMATION: /note= "Xaa= valine or serine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Xaa Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Xaa Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp Xaa Xaa Xaa Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Xaa Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Xaa Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Xaa Ala Trp Xaa Met Trp Ser Ser Asp Pro Ser Xaa Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Xaa Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Xaa Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Xaa Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Xaa Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Xaa (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3313 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCATTCCAAT TATAGGGATG CTCTTTTTTT GATIfTCTGGC CTATCCTTCT CATTTCATAG 2940 (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2172 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 723 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bacillus thuringiensis (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met Asp Pro Phe Ser Asn Tyr Ser Glu Gln Lys Tyr Pro Asp Ser Asn Asn Asn Gln Glu Leu Ile Thr Lys Ser Ser Ser Phe Tyr Ser Asp Thr Thr Asn Glu Asn Ala Lys Asn Tyr His Pro Ile Glu Gln Asp Ile Leu Lys Phe Thr Asn Gln Glu Phe Ser Asp Asn His Tyr Gln His Ser Asp Val Ser Asn Asp Ile Asn Ser Met Arg Asn Thr Leu Cys Lys Asp Leu Pro Pro Glu Thr Asn Met Ser Ile Tyr Asp Asn Leu Arg Ser Thr Val Thr Val Pro Ser Phe Ser Asn Gln Phe Asp Pro Ile Lys Phe Leu His Asp Ile Glu Ile Ala Ile Gln Thr Gly Ser Phe Ser Ala Leu Thr Gln Ser Asn Met Asn Gin Gly Gly Thr Asp Ile Asn Pro Met Leu Ile Ser Thr Phe Phe Lys Val Ala Ser Ser Leu Leu Pro Phe Pro Leu Ser Ser Leu Gly Ala Leu Ala Ser Phe Tyr Val Thr Asp Ser Gln Thr Gly Ala Met Ala Asn Leu Trp Arg Gln Met Val Asp Tyr Val Glu Lys Arg Ile Asp Ser Lys Ile Leu Asp Tyr His Asn Phe Ile Met Gly Ala Glu Leu Ala Ala Leu Asn Ala Ser Leu Lys Glu Tyr Ala Arg Val Val Lys Ile Phe Glu Asn Asp Met Asn Arg Met Ala Glu Pro Pro Ser Thr Gly Val Ile Thr Gln Phe Arg Ile Leu Asn Asp Asn Phe Ile Lys Tyr Ile Ala Lys Leu Gln Phe Ser Thr Asn Gln Ser Asp Leu Gln Tyr Pro Val Leu Thr Leu Pro Leu Arg Ala Gln Ala Cys Val Met His Leu Met Leu Leu Lys Asp Ala Thr Thr Ser Val Trp Gly Gln Gln Ile Asp Ser Gln Gln Leu Asn Gly Tyr Lys Ala Glu Leu Ile Arg Leu Ile Lys Val Tyr Thr Asn Asp Val Asn Thr Thr Tyr Asn Gln Gly Leu Glu Leu Glu Lys Ala Lys Pro Leu Asn Tyr Ser Asp Pro Glu Glu Tyr Leu Gln Ala Gly Arg Pro Asp Ile Ser Val Leu Arg Ser Asn Phe Lys Glu Val Met Lys Trp Asn Arg Val Ala Lys Tyr Lys Arg Gly Met Ala Met Ser Ala Leu Ser Leu Ala Ala Leu Phe Pro Thr Phe Gly Pro Asn Tyr Pro Lys Gln Ala Leu Lys Val Val Gln Ser Arg Gln Ile Phe Ala Pro Val Ile Gly Ile Pro Gly Gly Ile Thr Ser Gln Asp His Ser Gly Thr Phe Gly Ser Met Arg Phe Asp Val Lys Thr Tyr Asp Gln Ile Asp Ala Leu Arg Arg Leu Met Glu Leu Tyr Ile Gln Pro Leu Lys Ser Ala Tyr Phe Tyr Ile Tyr Glu Ser Asp Trp Lys Val Arg Ala Thr Tyr Val Asn Asp Tyr Ile Gly Lys Arg Gly Ser Asn Thr Gly Leu Ala Trp Gly Met Trp Ser Ser Asp Pro Ser Val Ile Tyr Thr Ser Ala Leu Gly Ala Ala Gly Tyr Ala Pro Asn Val Val Gly Val Arg Tyr Ser His Gly Gly Ser Tyr Thr Lys Gly Met Ala Pro Pro Asn Thr Asn Ala Tyr Ala Pro Phe Glu Phe Lys Tyr Pro Gly Tyr Lys Leu His Ser Val Ser Ala Tyr Gly Leu Ser Lys Ala Pro Asp Thr Ala Asp Ser Val Met Phe Gly Phe Arg Pro Val Leu Leu Glu Asn Glu Ala Asn Gln Leu Leu Thr Asp Thr Ala Leu Gln Ile Pro Ala Glu Ile Gly Ile Thr Asp Val Val Pro Ala Phe Gly Arg Thr Glu Glu Pro Ile Asn Gly Gln Asp Ala Ile Ile Ile Trp Glu Ser Phe Thr Ser Gly Phe Gly Phe Thr Tyr Thr Val Asp Ser Pro Gln Lys Gln Lys Tyr Lys Ile Ile Tyr Arg Ile Ala Asn Asn Leu Ser Ala Ser Thr Val Ser Leu Thr Tyr Asn Asn Gln Thr Phe Phe Thr Asp Ile Leu Asn Thr Ser Leu Asp Pro Asn Gly Val Arg Gly Asn Tyr Gly Ser Tyr Thr Leu Val Glu Gly Pro Ile Ile Glu Phe Ser Gln Gly Thr Asn Ile Phe Lys Leu Arg Ser Gln Lys Gly Glu Phe Ala Ile Asp Ser Ile Ile Phe Ser Pro Val Ser

Claims

1. A biologically pure culture of a microorganism strain comprising all of the biochemical characteristics of a Bacillus thuringiensis strain deposited at the International Depository Authority of Health Canada in Winnipeg under accession number IDAC010201-5, or a mutant thereof isolated from said strain, said mutant comprising all of said biochemical characteristics and producing a crystal protein having cytotoxicity against human cancer cells.

2. An isolated nucleic acid molecule comprising:
(a) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:2;
(b) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:8;
(c) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:14;
(d) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:13, with the proviso that said nucleotide sequence does not encode the amino acid sequence at positions 232 to 723 of SEQ ID NO:18;
(e) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:15, with the proviso that said nucleotide sequence does not encode the amino acid sequence at positions 232 to 723 of SEQ ID NO:18;
(f) a nucleotide sequence comprising the nucleotide sequence of SEQ ID NO:1 or 9;
(g) a nucleotide sequence encoding a crystal protein cytotoxic against at least one human cancer cell, said crystal protein having at least 94% identity with the complete amino acid sequence of SEQ ID NO:2;
(h) a nucleotide sequence encoding a crystal protein cytotoxic against at least one human cancer cell, said crystal protein having at least 97% identity with the complete amino acid sequence of SEQ ID NO:8;

(i) a nucleotide sequence completely complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g) and (h);
or Q) a nucleotide sequence encoding a crystal protein cytotoxic against at least one human cancer cell, which hybridizes under high stringency conditions to the nucleotide sequence in (i) wherein the high stringency conditions comprise hybridization in 5X SSC, 5X Denhardt's solution, 1% SDS and 100 µg/ml of carrier DNA at 65°C followed by washing in 0.2X SSC, 0.1 % SDS at 65°C.

3. An isolated polypeptide comprising:
(a) an amino acid sequence as set forth in SEQ ID NO:2;
(b) an amino acid sequence as set forth in SEQ ID NO:8;
(c) an amino acid sequence as set forth in SEQ ID NO:
14;
(d) an amino acid sequence as set forth in SEQ ID
NO:13, with the proviso that said amino acid sequence is not the sequence at positions 232 to 723 of SEQ ID NO:18;
(e) an amino acid sequence as set forth in SEQ ID
NO:15, with the proviso that said amino acid sequence is not the sequence at positions 232 to 723 of SEQ ID NO:18;
(f) a crystal protein having at least 94% identity with the complete amino acid sequence of SEQ ID NO:2, wherein said protein becomes cytotoxic upon treatment with trypsin; or (g) a crystal protein cytotoxic against at least one human cancer cell and having at least 97% identity with the complete amino acid sequence of SEQ ID NO:8.

4. A recombinant vector comprising the isolated nucleic acid molecule of claim 2.

5. A recombinant host cell comprising the vector of claim 4.

6. A method for making a recombinant vector comprising inserting the isolated nucleic acid molecule of claim 2 in a vector.

7. A recombinant method for producing the polypeptide of claim 3, comprising culturing the host cell of claim 5 under conditions such that said polypeptide is expressed and recovering said polypeptide.

8. An isolated antibody that binds specifically to:
(a) an amino acid sequence as set forth in SEQ ID NO:2;
(b) an amino acid sequence as set forth in SEQ ID NO:8;
(c) a crystal protein having at least 94% identity with the complete amino acid sequence of SEQ ID NO:2, wherein said protein becomes cytotoxic upon treatment with trypsin; or (d) a crystal protein cytotoxic against at least one human cancer cell and having at least 97% identity with the complete amino acid sequence of SEQ ID NO: 8.

9. An in vitro method of using the polypeptide of claim 3 for lysing a human cancer cell, comprising contacting the cell with a cytotoxic amount of the polypeptide.

10. The method of claim 9, wherein the cell is a HELA, TCS, HL-60, Jurkat, or Hep-G2 cell.

11. An in vitro method of testing the cytotoxicity of the polypeptide of claim 3 against a candidate cancer cell, comprising determining the EC50 of the polypeptide on the candidate cell, wherein the polypeptide is characterized as possessing cytotoxicity against the candidate cell if the of the polypeptide against the candidate cell is measurably lower than that against a normal T cell.

12. A method for obtaining a cytotoxic polypeptide, comprising contacting the polypeptide of claim 3 (a), (c) or (f) with trypsin.

13. A biologically pure culture of a microorganism strain comprising all of the biochemical characteristics of a Bacillus thuringiensis strain deposited at the International Depository Authority of Health Canada in Winnipeg under accession number IDAC010201-5.